BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Lowered by Zacks Research

BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

A number of other brokerages have also commented on BCRX. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 8th. JMP Securities lifted their target price on BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a “market outperform” rating in a report on Wednesday, October 15th. Evercore ISI reiterated an “in-line” rating and issued a $8.00 price target on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 1st. Citizens Jmp decreased their price target on BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating for the company in a research note on Wednesday. Finally, Wall Street Zen upgraded BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 26th. Ten analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $19.33.

BioCryst Pharmaceuticals Trading Up 6.1%

NASDAQ:BCRX opened at $7.17 on Tuesday. The stock’s 50-day moving average is $7.50 and its 200-day moving average is $8.68. BioCryst Pharmaceuticals has a 1-year low of $6.00 and a 1-year high of $11.31. The stock has a market cap of $1.51 billion, a P/E ratio of -39.83 and a beta of 1.09.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). The company had revenue of $159.40 million for the quarter, compared to analyst estimates of $162.91 million. During the same period in the previous year, the business posted ($0.07) EPS. BioCryst Pharmaceuticals’s revenue was up 36.1% compared to the same quarter last year. BioCryst Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that BioCryst Pharmaceuticals will post -0.36 EPS for the current year.

Insider Buying and Selling at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total value of $595,700.00. Following the completion of the sale, the director directly owned 65,352 shares of the company’s stock, valued at approximately $556,145.52. The trade was a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 5.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Arrowstreet Capital Limited Partnership lifted its position in BioCryst Pharmaceuticals by 2,103.7% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company’s stock valued at $38,336,000 after acquiring an additional 4,084,403 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of BioCryst Pharmaceuticals by 25,631.2% in the second quarter. Assenagon Asset Management S.A. now owns 3,620,637 shares of the biotechnology company’s stock valued at $32,441,000 after purchasing an additional 3,606,566 shares in the last quarter. Millennium Management LLC boosted its position in shares of BioCryst Pharmaceuticals by 382.6% during the first quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company’s stock valued at $28,597,000 after buying an additional 3,022,769 shares during the last quarter. Qube Research & Technologies Ltd boosted its position in shares of BioCryst Pharmaceuticals by 152.3% during the second quarter. Qube Research & Technologies Ltd now owns 2,373,489 shares of the biotechnology company’s stock valued at $21,266,000 after buying an additional 1,432,824 shares during the last quarter. Finally, Nuveen LLC bought a new stake in BioCryst Pharmaceuticals during the first quarter worth $10,677,000. 85.88% of the stock is owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.